A New Hope in Lung Cancer Treatment
Silevertinib Shows Significant Efficacy in Phase 2 Trials
Black Diamond Therapeutics has announced encouraging results from the second phase of trials for silevertinib, a drug targeting a specific type of lung cancer. The study revealed that 60% of patients responded positively to the treatment, including 25 partial responses and one complete response.
Trial Details
- Dosage: Patients received a daily dose of 200mg of silevertinib.
- Data Collection: Results were collected until November 3, 2025, with an average follow-up period of 7.2 months.
- Ongoing Study: The trial is still in progress, with more data expected in the future.
Effectiveness Against Brain Metastasis
The drug demonstrated strong results in controlling the spread of cancer to the brain, achieving an 86% response rate.
Side Effects
Most patients experienced side effects, but none were unexpected. Common side effects included:
- Rash
- Mouth sores
- Diarrhea
- Nail infections
Future Plans
Black Diamond Therapeutics plans to present more detailed results, including duration of responses and progression-free survival, at a medical meeting in the second half of 2026. The company is also exploring partnerships to further develop the drug.
New Trial for Glioblastoma
In other news, the company is preparing to launch a new trial for glioblastoma, a type of brain cancer. The trial is expected to begin in the first half of 2026 and will involve around 150 patients.
Financial Outlook
Black Diamond has sufficient funds to cover its expenses until at least the second half of 2028. Despite the promising news, the company's stock price has dropped by 23.77%, trading at $2.62 at the time of this report.
